Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays

• Published in: Proteomics. Clinical applications 2022-11, Vol.16 (6), p.e2100111-n/a
• Main Authors: Banerjee, Arghya, Ray, Arka, Barpanda, Abhilash, Dash, Ankita, Gupta, Ishika, Nissa, Mehar Un, Zhu, Heng, Shah, Abhidha, Duttagupta, Siddhartha P., Goel, Atul, Srivastava, Sanjeeva
• Format: Article
• Language: English
• Subjects: Acromegaly; Adenoma; Adenoma - genetics; Adrenocorticotropic hormone; Antibodies; Antigens; auto antibody; Autoantibodies; Biomarkers; Cell Adhesion Molecules, Neuronal; cushing's and nonfunctional adenomas; Dehydration; Design of experiments; DNA-Binding Proteins; DNA-directed RNA polymerase; Experimental design; Glioma; Humans; Meningioma; multiple reaction monitoring; Nerve Growth Factors; Nervous system diseases; Nuclear Proteins; Nucleoli; Peptidase; Peptidases; Pituitary; pituitary adenomas; Pituitary Neoplasms - genetics; protein microarray; Protein-tyrosine-phosphatase; Proteins; Proteome; Proteomes; RNA polymerase; RNA polymerase II; Serology; Transcription Factors; Tumors; Tyrosine
• ISSN: 1862-8346; 1862-8354
• DOI: 10.1002/prca.202100111

Purpose To identify the specific diagnostic biomarkers related to pituitary adenomas (PAs), we performed serological antibody profiles for three types of PAs, namely Acromegaly, Cushing's and Nonfunctional Pituitary Adenomas (NFPAs), using the human proteome (HuProt) microarray. This is the first study describing the serum autoantibody profile of PAs. Experimental Design We performed serological autoantibody profiling of four healthy controls, four Acromegaly, three Cushing's and three NFPAs patient samples to obtain their autoantibody profiles, which were used for studying expression, interaction and altered biological pathways. Further, significant autoantibodies of PAs were compared with data available for glioma, meningioma and AAgAtlas for their specificity. Results Autoantibody profile of PAs led to the identification of differentially expressed significant proteins such as AKNAD1 (AT‐Hook Transcription Factor [AKNA] Domain Containing 1), NINJ1 (Nerve injury‐induced protein 1), L3HYPDH (Trans‐3‐hydroxy‐L‐proline dehydratase), RHOG (Rho‐related GTP‐binding protein) and PTP4A1 (Protein Tyrosine Phosphatase Type IVA 1) in Acromegaly. Protein ABR (Active breakpoint cluster region‐related protein), ST6GALNAC6 (ST6 N‐acetylgalactosaminide alpha‐2, 6‐sialyltransferase 6), NOL3 (Nucleolar protein 3), ANXA8 (Annexin A8) and POLR2H (RNA polymerase II, I and III subunit H) showed an antigenic response in Cushing's patient's serum samples. Protein dipeptidyl peptidase 3 (DPP3) and reticulon‐4 (RTN4) exhibited a very high antigenic response in NFPA patients. These proteins hold promise as potential autoantibody biomarkers in PAs.